Health Technology
PureHealth | January 16, 2024
PureHealth, the largest healthcare platform in the Middle East, has announced the successful completion of its strategic acquisition of Circle Health Group, UK’s largest independent operators of hospitals, marking a significant milestone in the company's global expansion strategy. The completion of this deal, which has achieved regulatory approvals in record time, signifies PureHealth’s exceptional operational capabilities and commitment to international growth.
The completion of this transaction further strengthens PureHealth’s commitment to becoming a leading global player in healthcare. With a vision aligned with the UAE leadership to promote wellbeing and enhance healthcare services, PureHealth is dedicated to continuously improving patient experience and adopting the most advanced clinical practices. The company’s expansion into the UK healthcare market reflects its focus on advancing the science of longevity and unlocking time for humanity.
Hamad Al Hammadi, Chairman of the Board of Directors of PureHealth, said: “We are pleased to complete the acquisition of Circle in record time. This remarkable achievement epitomises PureHealth's operational excellence and strategic adaptability in broadening its international impact. After investing in Ardent Health USA, this is PureHealth’s second international acquisition, and we look forward to building our portfolio internationally.”
Farhan Malik, Founder and Managing Director of PureHealth, commented: “Completing the acquisition of Circle is a strategic leap forward for PureHealth. This acquisition is more than an expansion; it's a significant stride towards establishing PureHealth as a global healthcare platform. We are not just investing in the future of healthcare; we are shaping it to be more connected, innovative, and accessible on a global scale. This move aligns with our vision of pioneering a healthier future for all and underscores our commitment to elevating the global position of Abu Dhabi in the healthcare sector and revolutionising healthcare services globally. We look forward to fostering long term partnerships within the UK’s healthcare ecosystem.”
Valued at c.USD 1.2 billion before debt, this acquisition marks a significant investment in the future of healthcare, positioning PureHealth at the forefront of international healthcare innovation and service provision.
Building upon this significant momentum, PureHealth is advancing its expansion strategy in 2024. This strategic vision includes not only acquisitions in locally, but also international markets building a global healthcare platform.
As PureHealth moves forward with its strategic global expansion, it remains committed to its mission of delivering unrivalled healthcare experiences through innovation, technology-driven solutions, and collaboration. This transaction not only enhances PureHealth's services and presence in the international healthcare landscape but also solidifies the company’s position as a leader in the healthcare industry, dedicated to improving lives and fostering healthier communities worldwide, and taking PureHealth from Abu Dhabi to the World.
About PureHealth
By advancing the Science of Longevity, PureHealth is introducing the healthcare of the future from the United Arab Emirates to the rest of the world. PureHealth is the largest healthcare platform in the Middle East with an ecosystem that challenges lifespans and reimagines health spans. With 25+ hospitals, 100+ clinics, multiple diagnostic centres, health insurance solutions, pharmacies, health tech, procurement, investments and more. With groundbreaking innovations at the forefront of healthcare, the company is on a mission to unlock time for humankind.
Read More
Digital Healthcare, Medical Devices
Mindray North America | January 12, 2024
Mindray, a global developer of technologies and solutions for patient monitoring, anesthesia, and ultrasound, announced a five-year agreement with WakeMed Health & Hospitals (WakeMed), a leading health system in Raleigh, N.C. The nationally recognized 970-bed not-for-profit health care system selected Mindray's intuitive patient monitoring systems—including the BeneVision Distributed Monitoring System (DMS) and BeneVision N-series Patient Monitoring Systems—for its three hospitals.
As part of the agreement, approximately 2,300 monitoring devices will be installed in WakeMed's emergency and inpatient areas, across all acuity levels, to help assess and facilitate patient care, monitor vitals and condition changes in real-time, and provide seamless data integration during patient transport throughout its facilities.
"We are very excited to collaborate with WakeMed," stated Wayne Quinn, President, Mindray North America. Wayne continued, "Our purpose is to provide our customers with progressive technology that helps them deliver the highest quality care now and in the future, aligning with a shared vision of better healthcare for all. The contract with WakeMed underscores our commitment to ensuring the health system has access to tools and technologies that enable clinicians to work more efficiently while helping WakeMed fulfill its mission to improve the health and well-being of their community by providing outstanding and compassionate care to all."
"Mindray's monitoring technology will allow us to further improve patient safety, efficiency and clinical workflow as we continue to deliver life-changing care," said Neal Chawla, MD, Chief Medical Information Officer (CMIO) for WakeMed. "Alongside comprehensive patient monitoring, these innovative tools help prevent alarm fatigue and create a quieter, more restful environment for patients—a critical element to promote healing."
The BeneVision N-Series consists of six monitors with the same user interface. It allows healthcare facilities to choose their ideal display size and parameter capabilities, putting precise, relevant data at clinicians' fingertips. As the first-ever patient monitoring platform to incorporate capacitive touch screen technology across all of its monitors, N-Series enables clinicians to cut minutes off of clinical review, analysis and charting time, leading to increased efficiencies and driving positive patient outcomes. The N-Series' modular design expands, providing a scalable solution and the ability to flex from low acuity to high acuity, seamless data integration during transport, and flexible licensing options.
Mindray's BeneVision DMS provides continuous, real-time access and surveillance across large and small healthcare networks and integrates and displays patient information from networked bedside monitors, vital signs monitors, wireless transport solutions, and telemetry transmitters – supporting up to 1,200 devices across the enterprise, locally, and remotely. The BeneVision DMS enables clinicians to observe, manage and document a patient's condition in support of high-quality, patient-centric care, from admission to discharge.
About Mindray
Mindray is a leading developer, manufacturer, and supplier of medical device solutions and technologies used in healthcare facilities around the globe. We believe we can change lives by making the most advanced healthcare technology attainable for all. We do this by empowering healthcare professionals through innovative, high-value solutions that help create the next generation of lifesaving tools across three primary business segments: medical imaging, patient monitoring and life support, and in-vitro diagnostics. Mindray maintains its global headquarters in Shenzhen, China; Mindray North America is headquartered in Mahwah, New Jersey. Our Ultrasound Innovation Center is located in Silicon Valley, with additional facilities in major international markets around the world.
About WakeMed Health & Hospitals
Serving the community since 1961, WakeMed is a not-for-profit health care system founded and based in Raleigh, N.C. WakeMed exists to improve the health and well-being of our community by providing outstanding and compassionate care to all. WakeMed's 970-bed system comprises a network of facilities throughout the Triangle area, including three full-service hospitals, seven emergency departments, a dedicated Children's Hospital and Rehabilitation Hospital, more than 90 physician offices and Wake County's only Level I Trauma Center. WakeMed's mission-driven team includes more than 10,300 employees, 1,400 volunteers and 1,300 affiliated physicians, along with the more than 700 physicians and providers with WakeMed Physician Practices – all representing the best minds and the biggest hearts and the finest quality in health care and community health.
Read More
Medical Devices
Medtronic | January 08, 2024
Medtronic plc a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.
The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024. Medtronic will begin the phased commercial launch in Europe in the summer of 2024. Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor.
The MiniMed™ 780G system is Medtronic's most advanced insulin delivery system, automatically adjusting and correcting† glucose levels every 5 minutes.§ It's the world's only system with a Meal Detection™ feature‡ that is designed to reduce post-meal hyperglycemia when users occasionally forget to give themselves insulin or underestimate the number of carbs in their snacks or meal. The system, which is available with the world's only 7-day infusion set, also features one of the lowest glucose target settings (as low as 100 mg/dL) of any automated insulin delivery system. With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes. With both Simplera Sync™ sensor and the Guardian™ 4 sensor, no fingersticks are required.
"A challenging aspect of living with diabetes is counting carbohydrates and dosing the right amount of insulin before consuming snacks and meals. Many people underestimate their carbs, which can lead to high blood sugars (hyperglycemia). Prolonged hyperglycemia can lead to serious health problems impacting the eyes, major organs, and even cognitive function, which is particularly concerning in developing children," Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences "With its responsive algorithm, the MiniMed™ 780G system can help people living with diabetes even when they occasionally forget to bolus or undercount their carbs. The system takes on more of the work involved in diabetes management and helps alleviate mental burden."
"We're incredibly proud that the MiniMed™ 780G system continues to be the most widely used automated insulin delivery system in Europe since we launched it in 2020. Real-world data on over 100,000 users on the system across many geographies and cultures shows that when using recommended settings the system is delivering an average Time in Range of nearly 80%, raising the bar on what 'good' looks like2," said Que Dallara, EVP and President, Medtronic Diabetes. "With the introduction of Simplera Sync™ sensor, we're able to offer the proven benefits of our MiniMed™ 780G system with our newest and most comfortable sensor that can be applied in under 10 seconds."
The MiniMed™ 780G system with Simplera Sync™ sensor is indicated for ages 7+ and compatible with iOS and Android. Simplera Sync™ sensor is not approved by the FDA and is limited to investigational use in the U.S.
Simplera Sync™ sensor is designed to leverage Medtronic's advanced AID algorithm as part of its MiniMed™ 780G system while having a similar look and feel as the Simplera™ CGM. The Simplera™ CGM for integrated use with the InPen™ smart insulin pen received CE Mark in September 2023.
About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary.
Read More
Medical Devices
Canon Medical Systems | January 15, 2024
Canon Medical Systems Corporation and Olympus Corporation announced that we have reached an agreement to collaborate on Endoscopic Ultrasound Systems. Canon Medical will develop and manufacture diagnostic ultrasound systems used in Endoscopic Ultrasonography1 (EUS), and Olympus will perform the sales and marketing efforts. The aim of this collaboration between Canon's Aplio i8002 diagnostic ultrasound system for EUS and Olympus' Ultrasound Endoscope3 is to provide the market with advanced EUS equipment capable of delivering high-quality image diagnoses. Canon Medical and Olympus are focusing on technological advancements and enhancing diagnostic performance in the EUS field, with plans for global expansion, starting in Japan and Europe.
Canon Medical has a history of more than 100 years in the diagnostic imaging systems business, including X-ray diagnostic systems, CT, MRI, and ultrasound diagnostic systems, and provides products and services to more than 150 countries and regions worldwide. Canon Medical has been a leading company in the development of diagnostic ultrasound systems since the 1960s and has pioneered the development of A-mode (Amplitude display mode) systems for neurosurgery and linear electronic scanning systems, among others. Canon Medical's strengths lie in its advanced ultrasound image quality and proprietary technologies, such as D-THI, an image quality enhancement technology, and SMI, an imaging technology that enables the delineation of extremely slow and fine blood flow, which has been difficult to image in the past.
Olympus has contributed to elevating the standard of care through early detection, diagnosis and staging, and minimally invasive treatment since developing the world’s first practical gastrocamera. In the field of EUS, Olympus has worked closely with physicians to develop new equipment to enhance imaging and diagnostic methods and expand procedures, helping gain and maintain a high share of the global market.
Through our collaboration, the two companies will achieve further qualitative improvements in the quality of images and performance in diagnosis and minimally invasive treatment of EUS, ultimately contributing to facilitate the early detection of diseases.
Comment from Toshio Takiguchi, President and CEO, Canon Medical Systems Corporation
“We have been promoting our business with diagnostic imaging at its core under the philosophy of 'Made for Life,' which expresses our desire to contribute to medical care that protects precious lives. We have a long history in diagnostic ultrasound systems and have developed unique technologies that contribute to the early detection of diseases in cooperation with doctors around the world. We are very pleased to collaborate with Olympus, a leading endoscope manufacturer, in the EUS field, which we have not been able to cover adequately until now, to deliver superior solutions to more patients.”
Comment from Frank Drewalowski, Executive Officer and Endoscopic Solutions Division Head, Olympus Corporation
“Olympus aims to improve patients’ quality of life through early diagnosis made available with Endoscopic Ultrasound Systems. In the field of EUS, diagnostic ultrasound systems are very important, and we are pleased to have a cooperative relationship with Canon Medical, which has advanced ultrasound imaging technology. Canon Medical and Olympus will continue to introduce products and technology that address the needs of the patients, healthcare professionals, and the broader medical industry.”
This examination uses ultrasound attached to the tip of an endoscope to observe the outer organs (pancreas, gallbladder, bile ducts, liver, etc.) from the stomach and duodenum. Compared to the approach from the body surface, the target organs can be observed at close range, allowing detailed diagnosis with clearer images. In the diagnosis of pancreatic cancer, EUS is recognized as having the same diagnostic capability as contrast-enhanced CT and MRI in the "Guidelines for Pancreatic Cancer Treatment (2022)" in Japan. EUS-FNA (Endoscopic Ultrasonography-FNA: a test to collect tumor cells using an ultrasound endoscope) enables qualitative tissue diagnosis by minimally invasive cell and tissue collection and is established worldwide as a diagnostic method when pancreatic cancer is suspected. In addition to endoscopic retrograde cholangiopancreatography (ERCP), which is the first choice for stent placement for obstructive jaundice, endoscopic ultrasound-assisted biliary drainage (EUS-BD) using the EUS-FNA technique is now available. With the advent of these devices, the endoscopic treatment area of Interventional EUS has been attracting increasing attention in recent years.
About Canon Medical Systems
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, Diagnostic and Interventional X-ray, Ultrasound and MR, as well as a full suite of Healthcare IT solutions, across the globe. In line with our continued Made for Life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.
At Canon Medical, we work hand in hand with our partners - our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life
About Olympus
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world.
Read More